Myself i say 3 times that ,we will see down the road.....
but the price will go much higher
analysts at Cowen and Company initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a note issued to investors on Tuesday. The firm set an “outperform” rating and a $44.00 price target on the stock. Cowen and Company’s price target would indicate a potential upside of 96.60% from the company’s current price.
CAMBRIDGE, MA--(Marketwire - Sep 18, 2012) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status for the development of its lead infectious disease drug candidates, AVI-7288 and AVI-7537, for the treatment of Marburg virus and Ebola virus, respectively. Sarepta has been developing these platform-based therapeutics under a U.S. Department of Defense (DoD) contract managed by the Joint Project Manager Transformational Medical Technologies (JPM-TMT) Project Management Office, a component of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD).
The FDA's Fast Track program is designed to facilitate the development of, and expedite the review of, new drugs that have shown the potential to address an unmet medical need in a serious or life-threatening disease. Fast Track designated drugs qualify for Priority Review, an expedited review process available to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists.
The KCNH2 gene encodes the Kv11.1 potassium channel that conducts the rapidly activating delayed rectifier current in the heart. KCNH2 pre-mRNA undergoes alternative processing; intron 9 splicing leads to the formation of a functional, full-length Kv11.1a isoform, while polyadenylation within intron 9 generates a non-functional, C-terminally truncated Kv11.1a-USO isoform. The relative expression of Kv11.1 isoforms plays an important role in the regulation of Kv11.1 channel function and the pathogenesis of long QT syndrome. In this study, we identified cis-acting elements that are required for KCNH2 intron 9 poly(A) signal activity. Mutation of these elements decreased Kv11.1a-USO expression and increased the expression of Kv11.1a mRNA, protein and channel current. More importantly, blocking these elements by antisense morpholino oligonucleotides shifted the alternative processing of KCNH2 intron 9 from the polyadenylation to the splicing pathway, leading to the predominant production of Kv11.1a and a significant increase in Kv11.1 current. Our findings indicate that the expression of the Kv11.1a isoform can be upregulated by an antisense approach. Antisense inhibition of KCNH2 intronic polyadenylation represents a novel approach to increase Kv11.1 channel function.
August 18, 2014
Chris Garabedian, President and CEO Sarepta Therapeutics (SRPT), announced that the Phase IIb clinical study on its first product, eteplirsen, will have its results submitted to the FDA by the end of the year, with a launch slated for mid next-year if approved. He was speaking at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts. Sarepta Therapeutics targets therapies for the RNA molecule. The company’s lead drug development program is for Duchenne muscular dystrophy (DMD), which affects mostly boys and is 100% fatal, with most passing in their 20s. The Phase II tests for eteplirsen show it slows the decline in walking ability for DMD patients who take a six-minute walk test (6MWT)...
The man is trying very hard and is doing everything possible ,the only thing i see wrong is the people under him is not doing a great job but getting there..
You need to stop bashing him .
You must have some motives .
every CEO you praised ''bought shares'' then bashed like hell ,sold short''
just looking for a 24 week confirmation of production in a larger group.All the other exons in the new trial as well will be approved at the end of trial.
so you will see a exon 51 approval after 24 weeks or before and the others exons approved later.
only sarepta has the most research data and trial data that should get EUA over all the rest.
Sarepta is the only company with some human testing and more than any other in animal data..
and maybe a hot rush contract???????????
even a 4th grader can figure that
Mean Target: 110.36
Median Target: 110.00
High Target: 165.00